<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>From 1980 to 1987, three cases of <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) were encountered among 68 cases of <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> who survived more than three years from the diagnosis </plain></SENT>
<SENT sid="1" pm="."><plain>The incidence (4.8%) of secondary <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) is almost identical to previous reports, but case reports of <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> were rare </plain></SENT>
<SENT sid="2" pm="."><plain>In Japan, there are few reports of <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> patients who later developed <z:e sem="disease" ids="C0280745" disease_type="Neoplastic Process" abbrv="">secondary MDS</z:e> or <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>In our cases, none of the 31 patients treated with <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> developed <z:e sem="disease" ids="C0280745" disease_type="Neoplastic Process" abbrv="">secondary MDS</z:e>, while three of 37 patients treated with melphalan developed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>This difference is not statistically significant </plain></SENT>
</text></document>